We bring medicines to patients through clinical trial distribution services, pre-approval and unlicensed medicines access,
and commercialization of products.
Jeremy Broadis and @ME_Corbett are attending #bioeurope digital, October 26-29. Don't hesitate to reach out and get in touch to discuss launch partnerships for Europe or global pre-approval access #partnerships#specialtycare#rarediseases#earlyaccess
@InceptuaGroup receives approval of marketing authorization transfer of Jetrea® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion https://t.co/AMHyYMFGYB #Jetrea#vitreolysis#treatment#EC
Inceptua participated in an initiative to raise awareness of the challenges of access to treatment for patients suffering from #rarediseases: https://t.co/3snPdBXiPn. Don't hesitate to connect with @StuartBMAC and reach out with any questions you may have. #earlyaccess
We anticipate three key trends for #comparatorsourcing in #China: 1. continued action against low quality and counterfeited products, 2. improved quality of local generics, and 3. a focus on lower costs. Learn more by following the link, and go to page 68: https://t.co/VcipXAx6nq
Welcome the more than 280 people across the industry who have already registered to join our webinar, February 20 (3PM London/10AM New York), on #expanded access as a key component in the development and launch process. You still have the chance to join: https://t.co/O7rgjjZ6Jo
LUXEMBOURG / SAN FRANCISCO – 7th February 2020 – Inceptua and @portola_pharma have entered into an agreement whereby Inceptua will become Portola’s exclusive distribution partner for Ondexxya® in selected countries:
https://t.co/VJh5etEJwk
Thanks to everyone attending the @Expanded_Access Summit and the session on 'The Integration of #EarlyAccess into Treatment and Clinical Research' with Inceptua’s @StuartBMAC. Don't miss our free webinar, February 20 Click here to register: https://t.co/g6T2K9l1is
"Across #rarediseases (...) we share the same goal: Getting treatments to patients in need (...). In Europe it can take up to 1100 days for an #orphandrug to become available (...) Make treatment available faster through pre-approval access (...)." @ME_Corbett, #WODC2019.
Welcoming back the incomparable Stuart Bell, PhD to discuss the latest innovation in pragmatic trial design for #ExpandedAccess Jan. 27-29, 2020 https://t.co/LyxIWz0Gyc
Brilliant @JAMAOnc paper on single patient use #expandedaccess at @mskcc by Hyman et. al. 36.1% of products were in Phase 2, 39.4% in Phase 3, and an incredible 18.8% were in Phase 1. Authors call for routine prospective collection of efficacy data in expanded access. Fully agree